{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-094125","form_type":"8-K","ticker":"KALA","cik":"0001479419","company_name":"KALA BIO, Inc.","filed_at":"2025-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.080233+00:00","generated_at":"2026-05-17T05:23:44.143338+00:00","sec_items":["2.05","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"KALA BIO Phase 2b trial fails; KPI-012 development halted; workforce cut 51%","bullets":["CHASE Phase 2b trial of KPI-012 for PCED did not meet primary endpoint of complete healing at Week 8; secondary endpoints also failed.","Company ceases development of KPI-012 and MSC-S platform; will explore strategic options and engage with secured lender.","Board approved workforce reduction of ~19 employees (~51%); expected to complete in Q4 2025.","KPI-012 was well-tolerated with no treatment-related serious adverse events observed."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-094125","json":"https://secwatch.observer/filing/0001104659-25-094125.json","markdown":"https://secwatch.observer/filing/0001104659-25-094125.md","text":"https://secwatch.observer/filing/0001104659-25-094125.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479419/000110465925094125/0001104659-25-094125-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479419/000110465925094125/tm2527340d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:23:44.143338+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"444f8b4f2631821c71879740bfd997519a6ecf9a","claim":"KALA BIO, Inc. announced a restructuring affecting the Company's workforce (approximately 19 employees, or approximately 51%).","evidence_excerpt":"On September 28, 2025, the board of directors (the “Board”) of KALA BIO, Inc. (the “Company”) determined to cease development of KPI-012 and its mesenchymal stem cell secretome platform and to take steps to preserve cash as the Company explores its strategic options. In connection with such decisions, the Board approved a reduction in the Company’s workforce by approximately 19 employees, or approximately 51% (the “Reduction”).","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479419/000110465925094125/0001104659-25-094125-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Affected area","value":"the Company's workforce"},{"label":"Headcount","value":"approximately 19 employees, or approximately 51%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}